drugset
drugset / Trial / NCT07140809

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

NCT07140809 ↗

Phase 1/2 Recruiting 48 enrolled Shanghai JMT-Bio Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia

Timeline

Start
2025-09-09
Primary completion
2026-07-31
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject JMT202 Unknown — Subcutaneous

Indications

hypertriglyceridemia